Qureshi Zaheer, Jamil Abdur, Altaf Faryal, Siddique Rimsha, Fatima Eeshal, Dost Sara, Zelkowitz Richard Scott, Shah Shivendra
The Frank H. Netter M.D. School of Medicine at Quinnipiac University.
Department of Medicine, Samaritan Medical Centre.
Ann Med Surg (Lond). 2024 Jul 3;86(9):5314-5319. doi: 10.1097/MS9.0000000000002347. eCollection 2024 Sep.
This review aims to discuss the role and efficacy of Sacituzumab Govitecan in the management of breast cancer.
Breast cancer is the most prevalent type of cancer among women worldwide. This comprehensive review delves into the advancements brought about by Sacituzumab Govitecan in the treatment of metastatic triple-negative breast cancer (TNBC). With a focus on its mode of action, efficacious role, clinical trials, and comparative advantages over conventional chemotherapy, the review highlights the therapy's precision in targeting cancer cells through monoclonal antibodies. Sacituzumab Govitecan's ability to deliver a chemotherapeutic payload specifically to cancer cells with the Trop-2 receptor sets it apart from traditional chemotherapy, minimizing collateral damage and reducing severe side effects. The impact of Sacituzumab Govitecan on improving progression-free survival, tumor response rates, and, significantly, the quality of life for patients is discussed. This article also sheds light on ongoing trials, FDA recognition, and the therapy's potential to transform breast cancer treatment.
In conclusion, Sacituzumab Govitecan shows potential as an innovative therapeutic option for breast cancer, particularly in metastatic breast cancer and triple-negative breast cancer, but it warrants additional research.
本综述旨在探讨戈沙妥珠单抗在乳腺癌治疗中的作用及疗效。
乳腺癌是全球女性中最常见的癌症类型。本全面综述深入探讨了戈沙妥珠单抗在转移性三阴性乳腺癌（TNBC）治疗中带来的进展。该综述聚焦于其作用方式、有效作用、临床试验以及相对于传统化疗的比较优势，强调了该疗法通过单克隆抗体靶向癌细胞的精准性。戈沙妥珠单抗能够将化疗药物特异性地递送至表达Trop-2受体的癌细胞，这使其有别于传统化疗，最大限度地减少了附带损害并降低了严重副作用。文中讨论了戈沙妥珠单抗对改善无进展生存期、肿瘤反应率以及显著提高患者生活质量的影响。本文还阐述了正在进行的试验、美国食品药品监督管理局（FDA）的认可情况以及该疗法改变乳腺癌治疗的潜力。
总之，戈沙妥珠单抗显示出作为乳腺癌创新治疗选择的潜力，尤其是在转移性乳腺癌和三阴性乳腺癌中，但仍需进一步研究。
